Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00390325
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:59.588345+00:00
Published At
2018-12-21T00:00:00+00:00
Record Updated At
2024-02-06
Results Posted At
2018-12-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Hereditary Thyroid Gland Medullary Carcinoma", "Locally Advanced Thyroid Gland Medullary Carcinoma", "Multiple Endocrine Neoplasia Type 2A", "Multiple Endocrine Neoplasia Type 2B", "Recurrent Thyroid Gland Medullary Carcinoma", "Sporadic Thyroid Gland Medullary Carcinoma", "Stage III Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-02-06"
protocolSection.identificationModule.nctId
"NCT00390325"
protocolSection.identificationModule.officialTitle
"Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-12-21"

Study condition terms

  • Hereditary Thyroid Gland Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Thyroid Gland Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Multiple Endocrine Neoplasia Type 2A (protocolSection.conditionsModule.conditions)
  • Multiple Endocrine Neoplasia Type 2B (protocolSection.conditionsModule.conditions)
  • Recurrent Thyroid Gland Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Sporadic Thyroid Gland Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Thyroid Gland Medullary Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IV Thyroid Gland Medullary Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)
  • Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.